<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Li YD</submitter><funding>NCI NIH HHS</funding><pubmed_abstract>Small molecules that induce protein-protein interactions to exert proximity-driven pharmacology such as targeted protein degradation are a powerful class of therapeutics&lt;sup>1-3&lt;/sup>. Molecular glues are of particular interest given their favorable size and chemical properties and represent the only clinically approved degrader drugs&lt;sup>4-6&lt;/sup>. The discovery and development of molecular glues for novel targets, however, remains challenging. Covalent strategies could in principle facilitate molecular glue discovery by stabilizing the neo-protein interfaces. Here, we present structural and mechanistic studies that define a &lt;i>trans&lt;/i>-labeling covalent molecular glue mechanism, which we term "template-assisted covalent modification". We found that a novel series of BRD4 molecular glue </pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2023.02.14.528208</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9949066</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.</pubmed_title><pmcid>PMC9949066</pmcid><funding_grant_id>K00 CA253754</funding_grant_id><pubmed_authors>Lumpkin R</pubmed_authors><pubmed_authors>Qi J</pubmed_authors><pubmed_authors>Park PMC</pubmed_authors><pubmed_authors>Jin CY</pubmed_authors><pubmed_authors>Wang MY</pubmed_authors><pubmed_authors>Ebert BL</pubmed_authors><pubmed_authors>Slabicki M</pubmed_authors><pubmed_authors>Puvar K</pubmed_authors><pubmed_authors>Zou C</pubmed_authors><pubmed_authors>Hunkeler M</pubmed_authors><pubmed_authors>Yoon H</pubmed_authors><pubmed_authors>Ficarro SB</pubmed_authors><pubmed_authors>Sandoval B</pubmed_authors><pubmed_authors>Hassan MM</pubmed_authors><pubmed_authors>Fischer ES</pubmed_authors><pubmed_authors>Marto JA</pubmed_authors><pubmed_authors>Teng M</pubmed_authors><pubmed_authors>Sigua LH</pubmed_authors><pubmed_authors>Tavares I</pubmed_authors><pubmed_authors>Li YD</pubmed_authors><pubmed_authors>Tsai JM</pubmed_authors><pubmed_authors>Gray NS</pubmed_authors><pubmed_authors>Majewski FC</pubmed_authors><pubmed_authors>Nowak RP</pubmed_authors><pubmed_authors>Donovan KA</pubmed_authors><pubmed_authors>Xu S</pubmed_authors><pubmed_authors>Groendyke BJ</pubmed_authors><pubmed_authors>Ma MW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.</name><description>Small molecules that induce protein-protein interactions to exert proximity-driven pharmacology such as targeted protein degradation are a powerful class of therapeutics&lt;sup>1-3&lt;/sup>. Molecular glues are of particular interest given their favorable size and chemical properties and represent the only clinically approved degrader drugs&lt;sup>4-6&lt;/sup>. The discovery and development of molecular glues for novel targets, however, remains challenging. Covalent strategies could in principle facilitate molecular glue discovery by stabilizing the neo-protein interfaces. Here, we present structural and mechanistic studies that define a &lt;i>trans&lt;/i>-labeling covalent molecular glue mechanism, which we term "template-assisted covalent modification". We found that a novel series of BRD4 molecular glue </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-04T11:26:47.349Z</modification><creation>2025-04-04T11:26:47.349Z</creation></dates><accession>S-EPMC9949066</accession><cross_references><pubmed>36824856</pubmed><doi>10.1101/2023.02.14.528208</doi></cross_references></HashMap>